Aurobindo Pharma subsidiary Lannett Company launches generic Advair Diskus in the US

Lannett Company LLC, an arm of Hyderabad-based Aurobindo Pharma, has announced the launch of the generic version of Advair Diskus in the United States market. The product, which consists of fluticasone propionate and salmeterol inhalation powder, is a generic alternative to the medication originally developed by GSK plc.

According to a release issued by Aurobindo Pharma on Monday, this development represents a significant operational milestone for the firm. The company stated that the launch marks the first product from its inhalation pipeline to be commercialized in the US market. The move reflects the pharmaceutical firm's ongoing focus on expanding its portfolio of complex and differentiated inhalation products.

Advair Diskus is utilized as a combination therapy indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The entry of a generic alternative in the US market typically impacts pricing and accessibility for patients requiring long-term management therapies for these respiratory conditions.

Aurobindo Pharma, headquartered in Hyderabad, continues to build its presence in regulated international markets through its various operating subsidiaries, including Lannett Company LLC. Further details regarding production volumes or financial projections associated with the launch were not disclosed in the company's release.

"The commercialization of the first product from an inhalation pipeline in a highly regulated market like the United States is a notable step for a pharmaceutical company. Bringing complex generic formulations to global markets requires navigating stringent regulatory frameworks and manufacturing standards. For established pharmaceutical players, expanding into differentiated product segments helps diversify revenue streams and strengthens their market position in competitive international sectors." — Dr. Shishir Gupta, Founder & CEO, StartupLanes